Modified Live Vaccine Tutorial

Learn how to properly mix, store, handle and administer Modified Live Vaccines.

Product Description

PYRAMID® 4 is a single-dose vaccine aiding in the prevention of disease caused by bovine herpesvirus type 1 (IBR), parainfluenzavirus type 3 (PI3), bovine viral diarrhoea virus (BVDV) and bovine respiratory syncytial virus (BRSV). PYRAMID delivers enhanced efficacy with the help of the MetaStim™ adjuvant system, enhancing the animal’s response to the vaccine for greater protection.

Features and Benefits

Single-dose1,2 protection against BVD, IBR, PI3 and BRSV

  • Dual phase metabolisable stimulant
    • Enhances specific antibody response
    • Enhances cell-mediated immunity
  • Demonstrated cross-protection against virulent BVDV-2 challenge7,8

Dosage Information

  • Inject 2 ml subcutaneously or intramuscularly on the side of the neck
  • Annual revaccination required
  • See product information sheet for more complete information

Safety Information

  • A small percentage of animals may show transient mild injection site swelling.
  • Do not vaccinate within 21 days before slaughter.
  • Burn container and all unused contents.
  • Should an allergic reaction occur for any reason, intramuscular adrenaline should be administered.
  • Store in the dark at 2 - 8°C. Avoid freezing.
  • Do not use in pregnant cows or in calves nursing pregnant cows.

1. Index of Veterinary Specialities. October-December 2013. Volume 51. Number 4. South African Publication.
2. Data on file. Ingelheim Pharmaceuticals (Pty) Ltd, Animal Health Division.
3. Data on File. Ingelheim Pharmaceuticals (Pty) Ltd, Animal Health Division.
4. Cox JC, Coulter AR. Adjuvants – a classification and review of their modes of action. Vac 1997; 15(3):248-256.
5. Hjorth RN, Bonde GM, Piner ED, et al. The effect of Syntex adjuvant formulation (SAF-m) on humoral immunity to the influenza virus in the mouse. Vac 1997; 15(5):541-546.
6. Raychaudhuri S, Tonks M, Carbone F, et al. Induction of antigen-specific class I-restricted cyctoxic T cells by soluble proteins in vivo. Proc. Natl. Acad. Sci. USA. 1992; 89:8308-8312.
7. Allison AC. Squalene and squalane emulsions as adjuvants. Methods 1999; 19:87-93.
8. Fairbanks K, Schnackel J, Chase CCL. Evaluation of a modified live virus Type-1a bovine viral diarrhea virus vaccine (Singer strain) against a Type-2 (strain 980) challenge. Vet Therap 2003; 4(1):24-34.

Product Information Sheet